Labiotech.eu

News and Trends 4 Aug 2022

RoslinCT and Lykan Bioscience combine to create cell therapy CDMO

RoslinCT, a cell and gene therapy contract development and manufacturing organization (CDMO) developing life-changing therapies in Edinburgh’s BioQuarter, and Lykan Bioscience, a CDMO focused on cell-based therapies, have entered into a business combination agreement to form a global advanced therapies CDMO. The combined group will offer process development expertise and cGMP manufacturing for a range […]

August 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Aug 2022

PolyPid to receive millions for commercialization of infection-fighting drug

A drug to prevent surgical site infections (SSIs) in abdominal and cardiac surgeries in Europe is to be commercialized after two companies entered an exclusive licensing agreement. Israel-based PolyPid Ltd and UK-based ADVANZ PHARMA Corp. announced the agreement for lead drug candidate D-PLEX100 yesterday (August 3). Topline results Under the terms of the agreement, PolyPid will receive […]

August 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 4 Aug 2022

F2G to push anti-fungal agent with new $70M funding

F2G Ltd, a clinical-stage biopharma company focused on therapies to treat life-threatening rare fungal infections with a high unmet medical need, has announced $70 million of financing. This was co-led by new investors Forbion and Sofinnova Partners, with participation from existing investors, Novo Holdings, Morningside Ventures, Cowen Healthcare Investments and Advent Life Sciences. Nanna Lüneborg […]

August 4, 2022 - 2 minutesmins - By Jim Cornall

In Depth 4 Aug 2022

The biggest Asia-Pacific biotech investments in July 2022

China’s vaccine developer MaxHealth Biotechnology raised the biggest private biotech investment in the Asia-Pacific region in July 2022, followed by China Immunotech and Ruibo Bio. MaxHealth Biotechnology reigned supreme in the Asia-Pacific region’s private biotech investment sphere in July 2022, with a $74 million Series B round. The company will use the money to fuel […]

August 4, 2022 - 2 minutesmins - By Jonathan Smith

News and Trends 4 Aug 2022

New breast cancer treatment receives funding

Researchers at Queen’s University Belfast in Northern Ireland have received funding from Breast Cancer Now to search for new treatments inspired by COVID-19 vaccine innovation. The research team will adapt lessons from the development of COVID-19 vaccines in the hunt for new treatments for an aggressive form of breast cancer. Niamh Buckley and Helen McCarthy […]

August 4, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 3 Aug 2022

Patients with advanced cancer set to benefit from ProfoundBio’s new drug

Patients with ovarian, endometrial, breast, non-small cell lung cancers and mesothelioma could benefit from an antibody drug conjugate (ADC) after clearance of an investigational new drug (IND) was approved by the US Food and Drug Administration (FDA). ProfoundBio received the FDA’s ‘study may proceed’ letter today (August 3) to evaluate PRO1184, a folate receptor […]

August 3, 2022 - 2 minutesmins - By Liza Laws

News and Trends 3 Aug 2022

Full label approval given by FDA for eye disease drug, CIMERLI

Age-related neovascular (wet) macular degeneration (nAMD) and other serious retinal diseases can now be treated after the U.S. Food and Drug Administration (FDA) approved a biosimilar product interchangeable with an injection. The approval of CIMERLI (ranibizumab-eqrn) interchangeable with Lucentis, a ranibizumab injection was jointly announced by Polpharma Biologics BV, Formycon AG and Bioeq AG today […]

August 3, 2022 - 4 minutesmins - By Liza Laws

News and Trends 3 Aug 2022

Ascletis announces FDA clearance of oral drug to conduct study in mild to moderate COVID-19 patients

A randomized, placebo-controlled study in mild to moderate COVID-19 patients has been approved by the US Food and Drug Administration (FDA). The Investigational New Drug (IND) application for ASC10, an oral drug candidate targeting RNA-dependent RNA polymerase (RdRp) for COVID-19 was granted to China-based Ascletis Pharma Inc today (August 3), to conduct a Phase 1b […]

August 3, 2022 - 2 minutesmins - By Liza Laws

News and Trends 3 Aug 2022

The eyes have it – Visiox Pharma closes $7M seed round

Visiox Pharma, LLC, a privately-funded U.S. biopharmaceutical company focused on the development and commercialization of ophthalmic drugs to address highly prevalent diseases in need of new treatment options, has announced the closing of a $7 million seed round of financing. The raise was funded by the Founding Partners and a group of ophthalmic industry leaders. […]

August 3, 2022 - 2 minutesmins - By Jim Cornall

conveyor belt of medical vials for scale up production

News and Trends 3 Aug 2022

Poseida Therapeutics and Roche to focus on therapies for hematologic malignancies

Poseida Therapeutics, Inc. has entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. The global collaboration covers the research and development of multiple existing and novel off-the-shelf cell therapies against targets in multiple myeloma, B-cell lymphomas and other hematologic indications. “We are excited […]

August 3, 2022 - 4 minutesmins - By Jim Cornall

Sanofi drops amcenestrant clinical development program

News and Trends 3 Aug 2022

Allarity Therapeutics drug no longer commercially viable or in shareholders’ best interest

Allarity Therapeutics, after meeting with the US Food and Drug Administration (FDA), has decided a growth factor receptor drug it licensed from Novartis is no longer commercially viable or in the best interests of its shareholders. A type C advisory meeting was held between Allarity and the FDA to discuss a development path for dovitinib. […]

August 3, 2022 - 4 minutesmins - By Liza Laws

car-t therapy, combination therapy, car-t cell therapy, cancer therapy, blood cancer

More News! 3 Aug 2022

Allarity Therapeutics takes advice from its board and switches focus to combination therapies

US-based Allarity Therapeutics has made a decision to change tack and focus on combination therapy approaches while making the most of its current assets. The company says the new strategy, driven by its board of directors, aligns with the ongoing shift in oncology standard-of-care moving away from monotherapies. Instead it will veer towards more promising […]

August 3, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

RoslinCT and Lykan Bioscience combine to create cell therapy CDMO

PolyPid to receive millions for commercialization of infection-fighting drug

F2G to push anti-fungal agent with new $70M funding

The biggest Asia-Pacific biotech investments in July 2022

New breast cancer treatment receives funding

Patients with advanced cancer set to benefit from ProfoundBio’s new drug

Full label approval given by FDA for eye disease drug, CIMERLI

Ascletis announces FDA clearance of oral drug to conduct study in mild to moderate COVID-19 patients

The eyes have it – Visiox Pharma closes $7M seed round

Poseida Therapeutics and Roche to focus on therapies for hematologic malignancies

Allarity Therapeutics drug no longer commercially viable or in shareholders’ best interest

Allarity Therapeutics takes advice from its board and switches focus to combination therapies

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!